Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors

Digestion

Volumn 60, Issue 5, 1999, Pages 469-476

  Faiss, S ^a   Rath U ^e   Mansmann, U ^a   Caird, D ^b   Clemens, N ^b   Riecken, E O ^a   Wiedenmann, Bertram ^c,d  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b IDS SCHEER AG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

^e NONE

Author keywords

Lanreotide; Neuroendocrine tumor; Somatostatin analogues

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ALPHA INTERFERON; ANGIOPEPTIN; CHROMOGRANIN A; SEROTONIN; SOMATOSTATIN DERIVATIVE;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; FATIGUE; FEMALE; GALLSTONE; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER DYSFUNCTION; MALE; METASTASIS; NAUSEA; NEUROENDOCRINE TUMOR; PANCREAS INSUFFICIENCY; PANCREAS TUMOR; PRIORITY JOURNAL; SEROTONIN BLOOD LEVEL; SIDE EFFECT; STOMACH TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION; TASTE; TUMOR GROWTH; URINARY TRACT INFECTION;

ANTINEOPLASTIC AGENTS; CHI-SQUARE DISTRIBUTION; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PEPTIDES, CYCLIC; SOMATOSTATIN; TUMOR MARKERS, BIOLOGICAL;

EID: 0344132653     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007693     Document Type: Article

References (33)

1. Vinik AI, McLeod MK, Shapiro B, Lloyd RV, Cho K: Clinical features, diagnosis, and localization of carcinoid tumors and their management. Gastroenterol Clin North Am 1989;18: 865-896.
2. Basser RL, Green MD: Recent advances in carcinoids and gastrointestinal neuroendocrine tumors. Curr Opin Oncol 1991;3:109-120.
3. Öberg K: Chemotherapy and biotherapy in neuroendocrine tumors. Curr Opin Oncol 1993;5:110-120.
4. Ahnert-Hilger G, Scherübl H, Riecken E-O, Wiedenmann B: Classification of neuroendocrine cells; in Scherübl H, Hescheler J (eds): The Electrophysiology of Neuroendocrine Cells. Boca Raton, CRC Press, 1995, pp 11-23.
5. Wiedenmann B, John M, Ahnert-Hilger G, Riecken E-O: Molecular and cell biological aspects of neuroendocrine tumors of the gastroenteropancreatic system. J Mol Med 1998; 76:637-647.
6. Scherübl H, Buhr H, Faiss S, Zimmer T, Riecken E-O, Wiedenmann B: Neuroendocrine tumors of the gastroenteropancreatic system: Therapeutic advances. Onkologie 1996;19: 214-219.
7. Yamada Y, Reisine T, Law SF, Ihara Y, Kubota A, Kagimoto S, Seino M, Seino Y, Bell GI, Seino S: Somatostatin receptors, an expanding gene family: Cloning and functional characterization of human sstr 3, a protein coupled to adenyl cyclase. Mol Endocrinol 1992;6:2136-2142.1
8. John M, Meyerhof W, Richter D, Waser B, Schaer JC, Boese-Landgraf J, Neuhaus P, Scherübl H, Riecken E-O, Reubi JC, Wiedenmann B: Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut 1996;38:33-39.
9. Scherübl H, Hescheler J, Bychkov R, Cuber JC, John M, Riecken E-O, Wiedenmann B: Electrical activity and calcium channels in neuroendocrine cells. Ann NY Acad Sci 1994;733: 335-339.
10. Todisco A, Seva C, Takeuchi Y, Dickinson CJ, Yamada T: Inhibition of AP-1 function via SSTR2 mediates somatostatin inhibition of cell proliferation. Dig Dis Sci 1994;8:1788.
11. Lamberts SWJ, van der Lely AJ, de Herder WW, Holland LJ: Octreotide. N Engl J Med 1996;334:246-254.
12. Scherübl H, Wiedenmann B, Riecken E-O, Thomas F, Kommerell B, Räth U: Treatment of the carcinoid syndrome with a depot-formulation of the somatostatin-analogue lanreotide. Eur J Cancer 1994;6:1590-1591.
13. Kvols LK, Moertel CG, O'Connell MJ, Schutt AK, Rubin J, Hahn RG: Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986;315:663-666.
14. Wiedenmann B, Räth U, Rädsch R, Becker F, Kommerell B: Tumor regression of an ileal carcinoid under the treatment with the somatostatin analogue SMS 201-995. Klin Wochenschr 1988;6:75-77.
15. Saltz L, Trochanowsky B, Buckley M, Heffernan B, Niedzwicki D, Tao Y, Kelsen D: Octreotide as an antineoplastic agent in the treatment of functional and non-functional neuroendocrine tumors. Cancer 1993;72:244-248.
16. Arnold R, Trautmann ME, Creutzfeldt W, Benning R. Benning M, Neuhaus C, Jurgensen R, Stein K, Schafer H, Bruns C, Dennler HJ: Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996;38: 430-438.
17. Deftos LJ: Chromogranin A: Its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev 1991; 12:181-187.
18. Schürmann G, Raeth U, Wiedenmann B, Buhr H, Herfarth C: Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumours of the gastroenteropancreatic tract. World J Surg 1992;16:697-702.
19. Anthony L, Johnson D, Hande K, Shaff M, Winn S, Krozely M, Dates J: Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol 1993;32:217-223.
20. Eriksson B, Renstrup J, Iman H, Öberg K: High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects. Ann Oncol 1997;8:1041-1044.
21. Deguchi H, Deguchi K, Tsukada T, Murashima S, Iwasaki E, Tsuda M: Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide. Intern Med 1994;31: 100-102.
22. Taylor JE, Bogden AE, Moreau JP, Coy DH: In vitro inhibition of human small cell lung carcinoma (NCL-H69) growth by somatostatin analogue. Biochem Biophys Res Commun 1988; 153:81-86.
23. Siegel RA, Tolscavai L, Rudin M: Partial inhibition of the growth of tansplanted Dunning rat prostate tumors with the long-acting somatostatin analogue Sandostatin (SMS 201-995). Cancer Res 1988;153:4651-4655.
24. Liebow CR, Reilly C, Serrano M, Schally AV: Somatostatin analogues inhibit growth of pancreatic cancer stimulating tyrosine phosphatase. Proc Natl Acad Sci USA 1989;86:2001-2007.
25. Bodgen AE, Taylor JE, Moreau JP, Coy DH, LePage DJ: Response of human lung xenografts to treatment with a somatostatin analogue (somatuline). Cancer Res 1992;50:4360-4365.
26. Weckbecker G, Liu R, Tolscavai L, Bruns C: Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res 1992;52:4973-4978.
27. Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP: Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 1990;323:1246-1249.
28. Scherübl H, Bäder M, Fett U, Hamm B, Schmidt-Gayk H, Koppenhagen K, Dop FJ, Riecken E-O, Wiedenmann B: Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors. Gastroenterology 1993; 105:1705-1709.
29. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K. Imura H, Seino S, Seino Y: Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 1994;93:1321-1325.
30. Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, Capella G, Kalthoff H, Vaysse N, Susini C: Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 1996;56:1823-1827.
31. van Hagen PM: Somatostatin receptor expression in clinical immunology. Metabolism 1996; 45(suppl 1):86-87.
32. Sharma K, Patel YC, Srikant CB: Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 1996; 10:1688-1696.
33. Patel YC, Srikant CB: Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology 1994;135:2814-2845.